Precautions related to Dosage and Administration: Regpara has an effect of decreasing calcium in blood. Therefore, it should be confirmed that the patient's serum calcium level is not low (9.0 mg/dL (2.3 mmol/L) or more prior to administration.
The serum calcium level should be determined once a week at the start of administration and during the dose adjustment period, and at least once every two weeks during the maintenance period. If serum calcium level decreases to 8.4 mg/dL (2.1 mmol/L) or less, the following measures should be taken. (See Table 4.)

The serum calcium level should be determined before administration of Regpara so that the effect and safety of the drug may be properly evaluated. Furthermore, it is recommended that corrected serum calcium valuesNote) should be used as a guide in patients with hypoalbuminemia (serum albumin: <4.0 g/dL).
The serum PTH level should be periodically determined so that it may be maintained at the target level for management. It is recommended that the serum PTH level should be determined twice a month at the start of administration and during the dose adjustment period (about 3 months after the start of administration), and at least once a month after the serum PTH level is confirmed to be almost stable. The serum PTH level should be determined before administration of Regpara so that the effect and safety of the drug may be properly evaluated.
Note) Corrected serum calcium is calculated as follows: Corrected serum calcium (mg/dL) = Serum calcium (mg/dL) - Serum albumin (g/dL) + 4.0.